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II 11 recommend measurement of the ABI in all new patients with intermittent claudication. Because the ABI can be decreased even in asymptomatic PAD patients, it is the most commonly used screening test in Japan for PAD. 14 Scores for WIQ, the primary endpoint, were stratified by ranges of baseline ABI values. To calculate ABI, systolic blood pressure was measured in both arms and legs by cuff sphygmomanometry. According to a baseline ABI 0.8-<0.9, 0.5-<0.8, or <0.5, the patients were classified as having mild, moderate or severe PAD, respectively.
All patients gave informed consent to enter this study and for their individual data to be anonymously submitted to the sponsor.
Intervention
Patients received lipo-PGE1 5-10 μg once daily (usual recommended dose in Japan) by intravenous injection or infusion. Drug administration was performed according to the dosing instructions (package insert). Treatment of each individual patient was done at the discretion of attending physicians. Although no restriction was placed on the dose or dosing interval, the standard treatment period was set at 8 weeks.
Endpoints
Main outcome measures were the Japanese version of WIQ as proposed by the Japanese College of Angiology, 15 which was completed by the patients themselves, and physicians' assessments of subjective symptom scores before and after treatment. WIQ is a valid tool for detecting improvement or deterioration in daily walking ability of patients with intermittent claudication. 16 By asking questions designed to assist patients in describing their degree of difficulty in walking during the past week, the WIQ assesses walking ability on a score of 0 (unable to perform because of severe impairment) to 100 (no impairment). Symptoms such as "sense of coldness", "numbness", and "pain at rest" were graded as: 1, none; 2, mild; 3, moderate; and 4, severe; "pain at rest" was graded as: 1, no pain experienced; 2, pain experienced rarely (analgesics not needed); 3, sometimes need analgesic for pain; 4, regularly need analgesic for pain; and 5, could not sleep at night because of pain despite the use of analgesic. At the end of the study, physicians assessed global improvement in each of their patients on the basis of ABI score, symptoms, personal interviews etc.
Statistical Analysis
WIQ scores were regarded as discrete data, and a non-parametric statistical analysis was mainly used. No missing values were complemented. For data that included missing values, no score was calculated for any of the WIQ subscales. To examine the correlation between WIQ score and physician assessment, the Spearman rank correlation coefficient (R) was calculated. For comparison of scores before and after lipo-PGE1 treatment according to the severity of PAD, the Wilcoxon signed rank test was used. Subgroups were compared by Steel-Dwass test or Tukey test as the multiplicity adjustment. Exploratory analysis of the risk factors for a change in the WIQ score was done by multiple regression analysis. For all statistical tests, a 2-sided significance level of 5% was used. Statistical calculations were performed using SAS version 9.1.3 (SAS, Cary, NC, USA).
Results

Patients
Case report forms were collected from 524 patients at 74 institutions in Japan. Of these, 355 patients did not meet the inclusion criteria, so data for the remaining 169 patients were analyzed for efficacy. Of the 524 enrolled patients 521 were included in the analysis of safety after exclusion of 3 patients who did not receive lipo-PGE1.
Among the 169 patients included in the evaluation of efficacy the proportion of male patients was slightly higher (58.0%). Mean age (± SD) was 73.5±10.3 years; 78.7% were aged ≥65 years. Mean ABI at baseline was 0.69±0.14. The most frequent comorbid condition was hypertension (49.7%), followed by diabetes mellitus (30.2%) and dyslipidemia (23.7%). The major concomitant drugs were antiplatelet 
Effect of Lipo-PGE1 Treatment
In patients stratified across all baseline ABI values, statistically significant (P<0.01) improvements were found for all WIQ subscales following lipo-PGE1 treatment for the standard treatment period (ie, 8 weeks) ( Table 1) . Among the 169 patients analyzed for efficacy, ABI values were measured at both baseline and at the end of treatment period in 158 and of these, in all patients with ABI <0.9, the mean ABI increased from 0.69±0.14 at baseline to 0.77±0.17 at the end of treatment period, showing a statistically significant difference (P<0.001). Furthermore, improvement of ABI after lipo-PGE1 treatment tended to increase with the severity of PAD. Table 2 shows the scores for 3 symptoms ("sense of coldness", "numbness", and "pain at rest") at baseline and after lipo-PGE1 treatment. Statistically significant (P<0.01) improvements were noted for all, regardless of baseline ABI. No interpretation was possible, however, for scores of "ulcers" because of limited data. Table 3 shows the global improvement according to the baseline ABI. Global improvement tended to be greater in patients with more severe PAD at baseline. The proportion of patients with "slightly improved" or better global improve- Correlation Between WIQ Score and the Global Improvement and Symptom Scores Table 4 shows the Spearman rank correlation coefficients for correlation between the pre-and post-treatment change in the WIQ score and the physicians' assessments of global improvement.
In the overall patient group with ABI <0.9, R was statistically significant in all 4 WIQ subscales: "walking distance", "walking speed", and "stair climbing", R≤0.45; "pain", R=0.31. Thus the scores for each subscale correlated slightly or substantially with global improvement. In patients with mild PAD (ABI 0.8-<0.9), R was statistically significant for all 4 WIQ subscales. Significant correlations were also found in 3 subscales for patients with moderate PAD (ABI 0.5-<0.8; R≤0.44), whereas in those with severe PAD (ABI <0.5), a slight correlation was found between global improvement and "walking distance" (R≤0.26).
Global improvement and symptom scores correlated well ( Table 4 ). In particular, significant correlations were noted between global improvement and symptoms such as "sense of coldness" and "pain at rest", irrespective of the baseline ABI.
No interpretation was possible for the correlation coefficient in patients with ulcers because of the limited sample size (among patients with ABI 0.8-<0.9, n=2; 0.5-<0.8, n=7; <0.5, n=1).
In all patients (ABI <0.9), a "sense of coldness" correlated significantly with "pain" (R≤0.4), whereas slight correlations (R≤0.3) were found for other WIQ subscales. In patients with ABI 0.8-<0.9 significant correlations were noted between "sense of coldness" and "pain", "pain at rest" and "pain", and "pain at rest" and "stair climbing" (all R≤0.5) as well as between "numbness" and "pain" (R≤0.4). In patients with ABI 0.5-<0.8, a "sense of coldness" correlated significantly with "pain" and "walking speed" (both R≤0.4). In patients with ABI <0.5, "pain at rest" correlated significantly with "pain" (R≤0.4).
Safety
Nine adverse reactions were experienced by 9 (1.7%) of the 524 patients: rash (n=2), phlebitis (n=1), and vascular disorder (n=1), as well as the following 5 serious adverse reactions, each occurring in 1 patient: cerebral hemorrhage, asthma, cardiac failure, infection, and localized infection. These serious adverse reactions were assessed to have no definite causal relationship with lipo-PGE1.
Discussion
WIQ is a disease-specific patient questionnaire that has been validated as a useful instrument for measuring community walking ability (walking endurance and walking velocity) in individuals with PAD and intermittent claudication. 17 In the present study, lipo-PGE1 treatment resulted in significant improvements in walking ability as revealed by WIQ scores as well as by physicians' assessments of symptom scores and global improvement. 
Lipo-PGE1 for PAD
Overall, global improvement correlated highly significantly with the change in the WIQ scores of our PAD patients with ABI <0.9. Notably, in patients with relatively mild disease (ABI 0.8-<0.9) global improvement significantly correlated with all 4 WIQ subscales. Moreover, in patients with ABI 0.5-<0.8 significant correlations were noted in 3 WIQ subscales, whereas a slight correlation was found only for "walking distance" in severely affected patients with ABI <0.5. Significant correlations were also noted between various WIQ subscales and symptom scores as evaluated by physicians. Our results imply that improvements in a "sense of coldness" and "pain at rest" were largely responsible for enhancing the WIQ scores.
Physicians' assessments of global improvement and symptom scores correlated significantly (R≥0.5) in patients with ABI <0.5. Substantial correlation was found between assessments of global improvement and symptom scores regardless of ABI value. The present study confirms that physicians' assessments of their patients' symptoms were accurate.
Although the beneficial effects of prostaglandin E1 against PAD are well documented, its precise mechanism of action seems complex and multifactorial. Lipo-PGE1 exerts its peripheral vasodilation effect by increasing cAMP, decreasing cellular calcium ions, and relaxing vascular smooth muscle. Improved walking capacity might further promote vasodilation and enhance leg circulation. The peripheral vessels are collateral vessels and microvessels rather than occluded vessels, and their dilation may also induce local (ie, leg) antiinflammatory effects and thereby improve vascular endothelial function. There is evidence that prostaglandin E1 down-modulates soluble adhesion molecules involved in vascular inflammation, such as VCAM-1, 18 as well as levels of monocyte chemoattractant protein-1, an important chemokine implicated in proatherogenic foam cell recruitment and formation. 19 Hence, lipo-PGE1 may improve vascular endothelial function in addition to its vasodilating effect.
Building on earlier pioneering work on cell therapy for patients with critical limb ischemia (CLI), 20 Kajiguchi et al 7 recently reported encouraging results of a trial of autologous progenitor cell transplantation for therapeutic angiogenesis in a cohort of no-option patients with CLI. Although lipo-PGE1 has not been reported to contribute to PAD treatment by favorably influencing endothelial precursor cells, this agent is shown to induce neovascularization by increasing production of vascular endothelial growth factor 21 and has stimulated angiogenesis in a rat sponge model. 22 Thus lipo-PGE1 may elicit several anti-ischemic effects in the legs in concert.
In the present study, various antiplatelet agents, antipyretic analgesics, and prostaglandin derivatives were used concomitantly with lipo-PGE1. Therefore, to verify the contributory effect of lipo-PGE1, separate analyses were done before and after lipo-PGE1 treatment for groups using and not using each concomitant drug. In all subgroups, significant improvements of all WIQ subscale scores were found after lipo-PGE1 treatment (data not shown); there were no significant differences between patients using or not using concomitant drugs. Therefore, the clinical effect was probably related to lipo-PGE1 alone. Lipo-PGE1 can be expected to produce significant improvements regardless of the use of concomitant drugs for the treatment of PAD.
Our results agree with those of a randomized double-blind comparative study that showed clinical benefits of treatment with prostaglandin E1 in patients whose response was assessed by WIQ, as well as by a simplified version of SF-36, a general health-related QOL questionnaire. 23 Moreover, Fukuhara and Esato treated PAD patients with Liple ® for 2 months and observed improvements of both emotional and physical QOL based on the results of SF-36 and physicians' assessments of symptoms. 24 Therefore, our results from a disease-specific questionnaire, the WIQ, which also showed significant improvements related to lipo-PGE1 treatment, are in close accordance with those obtained from the widely used SF-36 tool.
Conclusions
Lipo-PGE1 (Liple ® ) significantly (P<0.01) improved WIQ scores and symptom scores in patients with PAD and an ABI <0.9. Physicians' assessments of global improvement significantly correlated with the WIQ scores. Our results suggest that WIQ is a valid tool for evaluating therapeutic response, and that lipo-PGE1 improves walking ability and QOL as self-evaluated by patients with PAD.
